Tag Archives: SRPT

Top Blue Chip Stocks For 2019

&l;p&g;&l;img class=&q;dam-image shutterstock size-large wp-image-1106738453&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/1106738453/960×0.jpg?fit=scale&q; data-height=&q;640&q; data-width=&q;960&q;&g; Shutterstock

What if I told you there&a;rsquo;s a way you can buy your favorite blue chips and get a dividend &l;i&g;up to 6 times bigger&l;/i&g; than what these stocks pay today?

Let&a;rsquo;s be honest: with an income stream like that, backed by household names like &l;b&g;Pfizer &l;/b&g;and &l;b&g;AT&a;amp;T&l;/b&g;&a;mdash;more on these two stocks below&a;mdash;you&a;rsquo;d leap at the chance, right?

The truth is, you&a;rsquo;d be crazy not to.

Well, now you can. And today I&a;rsquo;m going to show you exactly how to do it&a;mdash;and 2 quick moves to get you there instantly.

&l;b&g;Like Buying Cheap in 2009 &a;hellip; and Knowing What Happens Next&l;/b&g;

Funny thing is, for a brief, shining moment in the not-so-distant past (early March 2009), many blue chips actually &l;i&g;did&l;/i&g; deliver payouts of 7%, 10% and more.

Top Blue Chip Stocks For 2019: Freshpet, Inc.(FRPT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Freshpet (NASDAQ:FRPT) – Research analysts at William Blair reduced their Q2 2018 earnings estimates for shares of Freshpet in a research note issued to investors on Monday, May 7th. William Blair analyst J. Andersen now expects that the company will post earnings per share of ($0.09) for the quarter, down from their prior forecast of ($0.04). William Blair also issued estimates for Freshpet’s Q4 2018 earnings at $0.10 EPS and FY2018 earnings at ($0.07) EPS.

  • [By Max Byerly]

    Shares of Freshpet Inc (NASDAQ:FRPT) have been assigned a consensus rating of “Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation, three have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $20.60.

  • [By Jon C. Ogg]

    Freshpet Inc. (NASDAQ: FRPT) was maintained as Neutral but the target price was raised to $36 from $32 at Credit Suisse.

    Harpoon Therapeutics Inc. (NASDAQ: HARP) was started as Outperform and assigned a $23 price target (versus a $17.01 close) at Wedbush Securities.

  • [By Motley Fool Transcribers]

    Freshpet Inc  (NASDAQ:FRPT)Q4 2018 Earnings Conference CallFeb. 26, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

Top Blue Chip Stocks For 2019: Alaska Air Group, Inc.(ALK)

Advisors’ Opinion:

  • [By Adam Levine-Weinberg]

    The oil rally has cooled off this month, over recent reports that have alleviated investors’ worries about a serious oil shortage. Lower jet fuel prices should help all of the airlines, but two could benefit disproportionately: Spirit Airlines (NYSE:SAVE) and Alaska Air (NYSE:ALK).

  • [By Adam Levine-Weinberg]

    The last couple of years have not been kind to JetBlue Airways (NASDAQ:JBLU) and Alaska Air Group (NYSE:ALK). Rising fuel prices have pinched profitability across the U.S. airline industry, but due to competitive dynamics and other factors, JetBlue and Alaska have had more trouble offsetting these cost headwinds than some other carriers.

  • [By Todd Shriber, ETF Professor]

    The analyst highlighted American Airlines Group Inc. (NASDAQ: AAL), Delta Airlines Inc. (NYSE: DAL), Southwest Airlines Co. (NYSE: LUV) and Alaska Air Group Inc. (NASDAQ: ALK) as among the industry's best-positioned names. The quartet combines for over 38 percent of JETS' roster.

Top Blue Chip Stocks For 2019: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By ]

    Some of my readers may know Sarepta (Nasdaq: SRPT) well. This $9 billion gene-therapy company already has an FDA-approved product. Exondys 51, the first-ever FDA-approved treatment for a rare but deadly genetic disease called Duchenne muscular dystrophy (DMD), is already on the market. And just last month, the FDA granted priority review for SRPT’s second treatment for DMD, golodirsen, for DMD patients with a different genetic mutation.

  • [By WWW.GURUFOCUS.COM]

    For the details of ETF Portfolio Partners, Inc.’s stock buys and sells, go to www.gurufocus.com/StockBuy.php?GuruName=ETF+Portfolio+Partners%2C+Inc.

    These are the top 5 holdings of ETF Portfolio Partners, Inc.Vanguard Total Stock Market (VTI) – 194,472 shares, 17.91% of the total portfolio. Shares added by 1.13%iShares Core U.S. Aggregate Bond (AGG) – 254,189 shares, 17.72% of the total portfolio. Shares added by 3.15%iShares Russell 1000 (IWB) – 98,181 shares, 9.78% of the total portfolio. Shares added by 0.56%Vanguard FTSE Developed Markets (VEA) – 322,914 shares, 9.08% of the total portfolio. Shares added by 1.20%iShares S&P 500 Value (IVE) – 108,531

  • [By Keith Speights]

    Three biotech stocks — Solid Biosciences (NASDAQ:SLDB), Sarepta Therapeutics (NASDAQ:SRPT), and Heron Therapeutics (NASDAQ:HRTX) — soared this week by 30% or more thanks to news that brought smiles to investors’ faces. Here’s what drove these stocks higher and whether or not they’re smart picks to buy now.

  • [By Angelica LaVito]

    CAMBRIDGE, Mass.,June 19, 2018 (GLOBE NEWSWIRE) –Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced that at the Company’s R&D Day,Jerry Mendell, M.D. of Nationwide Children’s Hospital presented positive preliminary results from its Phase 1/2a gene therapy clinical trial assessing AAVrh74.MHCK7.micro-Dystrophin in individuals with Duchenne muscular dystrophy (DMD). Dr. Mendell presented the following preliminary data on the first three patients enrolled in the study:

Top Blue Chip Stocks For 2019: UFP Technologies Inc.(UFPT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    UFP Technologies (NASDAQ: UFPT) and China XD Plastics (NASDAQ:CXDC) are both small-cap industrial products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

  • [By Ethan Ryder]

    Media coverage about UFP Technologies (NASDAQ:UFPT) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. UFP Technologies earned a daily sentiment score of 0.03 on Accern’s scale. Accern also assigned headlines about the industrial products company an impact score of 47.0533500754779 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

  • [By Logan Wallace]

    China XD Plastics (NASDAQ: CXDC) and UFP Technologies (NASDAQ:UFPT) are both small-cap basic materials companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, institutional ownership, earnings, risk and valuation.

Top 10 Performing Stocks To Own Right Now

LISTEN TO ARTICLE 3:18 SHARE THIS ARTICLE Facebook Twitter LinkedIn Email

BOE Technology Group Co.’s stock market reversal is dramatic even by China’s outsized standards. It took less than a year for the Apple Inc. supplier to go from one of the nation’s best-performing stocks to among its worst — a precipitous selloff that may not be over.

China’s largest maker of screens for TVs and phones shed more than 32 percent of its value this year, the steepest decline among the 50 biggest companies listed in Shanghai and Shenzhen. That was prompted by ballooning supply and plunging prices for the large screens that comprise most of its business. Even earning a coveted spot on Apple’s list of top 200 suppliers couldn’t overcome fears that demand-supply imbalances will persist, analysts say.

Top 10 Performing Stocks To Own Right Now: Interactive Brokers Group, Inc.(IBKR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Interactive Brokers Group (NASDAQ:IBKR) had its price target cut by SunTrust Banks to $71.00 in a research report sent to investors on Wednesday. They currently have a $65.34 rating on the financial services provider’s stock. SunTrust Banks also issued estimates for Interactive Brokers Group’s Q3 2018 earnings at $0.54 EPS, Q4 2018 earnings at $0.59 EPS, FY2018 earnings at $2.34 EPS, Q1 2019 earnings at $0.60 EPS, Q2 2019 earnings at $0.64 EPS, Q3 2019 earnings at $0.66 EPS, Q4 2019 earnings at $0.70 EPS and FY2019 earnings at $2.60 EPS.

  • [By Stephan Byrd]

    Interactive Brokers Group (NASDAQ: IBKR) and Charles Schwab Co. Common Stock (NYSE:SCHW) are both large-cap finance companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, valuation, earnings, analyst recommendations, profitability and risk.

  • [By Joseph Griffin]

    Here are some of the headlines that may have effected Accern Sentiment Analysis’s analysis:

    Get Interactive Brokers Group alerts:

    What Could Attract Investors to Interactive Brokers (finance.yahoo.com) Reviewing Charles Schwab (SCHW) and Interactive Brokers Group (IBKR) (americanbankingnews.com) Interactive Brokers Group (IBKR) Presents At Sandler O’Neill’s Global Exchange And Brokerage Conference – Slideshow (seekingalpha.com) Should You Invest In The Financial Stock Interactive Brokers Group Inc (NASDAQ:IBKR)? (finance.yahoo.com) Interactive Brokers Welcomes New Bond Disclosure Rules (finance.yahoo.com)

    Shares of Interactive Brokers Group traded up $1.20, reaching $71.38, during midday trading on Friday, according to MarketBeat Ratings. 1,131,168 shares of the company were exchanged, compared to its average volume of 859,815. The stock has a market cap of $29.39 billion, a PE ratio of 46.65, a PEG ratio of 1.65 and a beta of 0.95. Interactive Brokers Group has a one year low of $36.23 and a one year high of $80.32.

  • [By Dustin Blitchok]

    The European Union’s General Data Protection Regulation takes effect May 25, and Steve Sanders, the executive vice president of marketing and product development at Interactive Brokers (NASDAQ: IBKR), described it as the “bane of my existence.” Compliance with the regulations is taking resources from other products at the online brokerage, he said.

  • [By Max Byerly]

    Compass Point started coverage on shares of Interactive Brokers Group (NASDAQ:IBKR) in a research note published on Tuesday. The brokerage issued a neutral rating and a $74.00 price target on the financial services provider’s stock.

Top 10 Performing Stocks To Own Right Now: Park-Ohio Holdings Corp.(PKOH)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Park-Ohio (PKOH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Park-Ohio (PKOH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Park-Ohio (NASDAQ: PKOH) and Materion (NYSE:MTRN) are both small-cap industrial products companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

  • [By Logan Wallace]

    Park-Ohio (NASDAQ: PKOH) and Shiloh Industries (NASDAQ:SHLO) are both small-cap industrial products companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Top 10 Performing Stocks To Own Right Now: Monotype Imaging Holdings Inc.(TYPE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Here are some of the media stories that may have effected Accern Sentiment Analysis’s rankings:

    Get Monotype Imaging alerts:

    Should You Be Holding Monotype Imaging Holdings Inc (NASDAQ:TYPE)? (finance.yahoo.com) Monotype Imaging Holdings Inc. (TYPE) Forecasted to Earn Q1 2019 Earnings of $0.07 Per Share (americanbankingnews.com) Monotype Partners with PKU Founder Information Industry Group to Bring Latin Typefaces to Enterprise Brands and Creative Professionals in China (finance.yahoo.com) $59.42 Million in Sales Expected for Monotype Imaging Holdings Inc. (TYPE) This Quarter (americanbankingnews.com) Introducing the Walbaum Typeface: the Restoration of a Warm and Stylish Serif Design That Has Nearly Limitless Applications (finance.yahoo.com)

    TYPE has been the topic of a number of research analyst reports. B. Riley raised shares of Monotype Imaging from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $24.50 to $31.00 in a research report on Tuesday, February 20th. Zacks Investment Research raised shares of Monotype Imaging from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a research report on Tuesday, February 27th. ValuEngine raised shares of Monotype Imaging from a “sell” rating to a “hold” rating in a research report on Tuesday, February 20th. TheStreet downgraded shares of Monotype Imaging from a “b” rating to a “c+” rating in a research report on Friday, April 27th. Finally, BidaskClub downgraded shares of Monotype Imaging from a “hold” rating to a “sell” rating in a research report on Saturday, May 12th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the stock. Monotype Imaging presently has an average rating of “Hold” and an average p

  • [By Joseph Griffin]

    Monotype Imaging (NASDAQ:TYPE) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

  • [By Max Byerly]

    Zscaler (NASDAQ: ZS) and Monotype Imaging (NASDAQ:TYPE) are both computer and technology companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Monotype Imaging (NASDAQ:TYPE) from a sell rating to a hold rating in a research report report published on Tuesday morning.

Top 10 Performing Stocks To Own Right Now: Jazz Pharmaceuticals Inc.(JAZZ)

Advisors’ Opinion:

  • [By Keith Speights]

    But at least three of the biotechs singled out by the FDA deserve to be on another list — investors’ buy lists. Here’s why Celgene (NASDAQ:CELG), Gilead Sciences (NASDAQ:GILD), and Jazz Pharmaceuticals (NASDAQ:JAZZ) look like great stock picks right now.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    Private Capital Advisors Inc. acquired a new position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the second quarter, HoldingsChannel reports. The institutional investor acquired 24,200 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,170,000.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Jazz Pharmaceuticals (JAZZ)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Here are some of the news headlines that may have impacted Accern’s rankings:

    Get Jazz Pharmaceuticals alerts:

    Jazz Pharmaceuticals Presents Long-Term Safety and Efficacy Data from Phase 3 TONES 5 Study of Solriamfetol for Excessive Sle… (advfn.com) Jazz Pharmaceuticals (JAZZ) Given a $194.00 Price Target at Royal Bank of Canada (americanbankingnews.com) Analyzing Jazz Pharmaceuticals (JAZZ) & Celyad (CYAD) (americanbankingnews.com) Global Marine Pharmaceuticals Market Growing at a CAGR of 7.28% to 2022 (empowerednews.net) Physicians Unaware of Neurologic Effects Related to Obstructive Sleep Apnea, Finds Jazz Pharmaceuticals Survey (sleepreviewmag.com)

    Shares of Jazz Pharmaceuticals traded up $1.75, hitting $170.75, during trading on Friday, MarketBeat reports. 928,650 shares of the company were exchanged, compared to its average volume of 466,308. The firm has a market capitalization of $10.11 billion, a price-to-earnings ratio of 17.86, a price-to-earnings-growth ratio of 0.87 and a beta of 0.97. Jazz Pharmaceuticals has a fifty-two week low of $128.58 and a fifty-two week high of $171.76. The company has a quick ratio of 2.88, a current ratio of 3.00 and a debt-to-equity ratio of 0.55.

Top 10 Performing Stocks To Own Right Now: Videocon d2h Limited(VDTH)

Advisors’ Opinion:

  • [By Logan Wallace]

    Videocon d2h (NASDAQ: VDTH) and MSG Networks (NYSE:MSGN) are both small-cap consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings and institutional ownership.

  • [By Joseph Griffin]

    Videocon d2h (NASDAQ: VDTH) and DISCOVERY COMMUNICATIONS INC. Common Stock (NASDAQ:DISCA) are both consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Top 10 Performing Stocks To Own Right Now: Murphy Oil Corporation(MUR)

Advisors’ Opinion:

  • [By Logan Wallace]

    Clinton Group Inc. purchased a new stake in Murphy Oil Co. (NYSE:MUR) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 14,491 shares of the oil and gas producer’s stock, valued at approximately $489,000.

  • [By Stephan Byrd]

    Murphy Oil Co. (NYSE:MUR) has earned an average rating of “Hold” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, seven have issued a hold recommendation, two have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $31.56.

Top 10 Performing Stocks To Own Right Now: Gold Standard Ventures Corporation(GSV)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Gold Standard Ventures Corp (NYSEAMERICAN:GSV) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 6,511,796 shares, a drop of 7.7% from the April 30th total of 7,056,069 shares. Based on an average daily volume of 268,131 shares, the short-interest ratio is currently 24.3 days. Approximately 5.9% of the company’s stock are sold short.

Top 10 Performing Stocks To Own Right Now: GRAVITY Co. Ltd.(GRVY)

Advisors’ Opinion:

  • [By Cooper Creagan]

    For example, if you had taken five minutes to set up a Night Trade on Gravity Co. (Nasdaq: GRVY) in October, you could’ve tripled your money, and then some.

  • [By Max Byerly]

    ILLEGAL ACTIVITY WARNING: “Gravity (GRVY) Receives Coverage Optimism Score of 0.17” was first published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at www.tickerreport.com/banking-finance/3382037/gravity-grvy-receives-coverage-optimism-score-of-0-17.html.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Gravity (NASDAQ:GRVY) from a strong sell rating to a sell rating in a research note issued to investors on Tuesday morning.

Top 10 Performing Stocks To Own Right Now: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By Shane Hupp]

    Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.

  • [By Stephan Byrd]

    Trexquant Investment LP acquired a new position in Sarepta Therapeutics (NASDAQ:SRPT) in the first quarter, Holdings Channel reports. The institutional investor acquired 7,135 shares of the biotechnology company’s stock, valued at approximately $529,000.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    Three biotech stocks — Solid Biosciences (NASDAQ:SLDB), Sarepta Therapeutics (NASDAQ:SRPT), and Heron Therapeutics (NASDAQ:HRTX) — soared this week by 30% or more thanks to news that brought smiles to investors’ faces. Here’s what drove these stocks higher and whether or not they’resmart picks to buy now.

  • [By Chris Lange]

    Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares skyrocketed on Tuesday after the firm presented positive preliminary results from its midstage Duchenne muscular dystrophy (DMD) trial. Specifically, the results came from Sareptas Phase 1/2a gene therapy clinical trial assessing AAVrh74.MHCK7.micro-Dystrophin in individuals with DMD.

  • [By Logan Wallace]

    Barclays upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from an equal weight rating to an overweight rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $107.00 target price on the biotechnology company’s stock, up from their prior target price of $55.00.

Top 10 Performing Stocks To Own Right Now: Saul Centers, Inc.(BFS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Teachers Insurance & Annuity Association of America purchased a new position in shares of Saul Centers, Inc. (NYSE:BFS) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 13,437 shares of the real estate investment trust’s stock, valued at approximately $685,000. Teachers Insurance & Annuity Association of America owned approximately 0.06% of Saul Centers at the end of the most recent quarter.

  • [By Logan Wallace]

    Shares of Saul Centers, Inc. (NYSE:BFS) have been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and one has given a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $54.50.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Saul Centers (BFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Saul Centers (BFS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Value Stocks For 2018

I wrote a detailed article on Amira Nature Foods (NYSE: ANFI) a month ago, so please read it if before watching the below video if you are not familiar with ANFI.

Since then, ANFI’s stock price has increased by about 30% and I wanted to give an update about my views on ANFI’s fair value and fair market value.

Additionally, I have analyzed the real value of ANFI’s land plots, the 20.3 acres in Guargon, South of New Dehli, and 48 acres in Karnal, north of New Dehli. I must say that for the first time I agree with the short attacks that have plagued ANFI in the last few years. The balance sheet values and the real values don’t match. However, my calculations show far higher values than those on the balance sheet. Please enjoy the video and I look forward to your comments and insights about ANFI.

Disclosure: I am/we are long ANFI.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.

Hot Value Stocks For 2018: Silicon Graphics International Corp(SGI)

Advisors’ Opinion:

  • [By Peter Graham]

    A long term performance chart shows Cray Incstill and by far outperforming other supercomputer players likelarge caps International Business Machines Corp (NYSE: IBM) andHewlett-Packard Company (NYSE: HPQ) plus small cap Silicon Graphics International Corp (NASDAQ: SGI):

Hot Value Stocks For 2018: Peugeot S.A. (PUGOY)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    Yes, you read that correct! General Motors (NYSE: GM) will probably not settle for just a new 52-week high and will aim to take out the 2013 peak of $41.85. With talks about the Opel sellout to PSA Group (OTCPK:PEUGF) (OTCPK:PUGOY) progressing at a rate much faster than I had anticipated, a (likely) deal announcement on Monday will pave the way for new all-time highs.

  • [By John Rosevear]

    It’s official: General Motors (NYSE:GM) will sell its long-troubled Opel subsidiary to French automaker Peugeot S.A. (NASDAQOTH:PUGOY) for about $2.3 billion, in a deal expected to close later this year.

  • [By Adam Levine-Weinberg]

    Now, the General is thinking about ditching Europe for good by selling its European operations to French automaker Peugeot (NASDAQOTH:PUGOY). As long as Peugeot is willing to pay a reasonable price, selling Opel is GM’s best course of action.

Hot Value Stocks For 2018: Sarepta Therapeutics, Inc.(SRPT)

Advisors’ Opinion:

  • [By Lisa Levin]

    Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were also up, gaining 16 percent to $47.52 following the announcement of positive results in its study for the treatment of Duchenne Muscular Dystrophy.

  • [By Ben Levisohn]

    Skorney’s namesVertex Pharmaceuticals (VRTX),Sarepta Therapeutics (SRPT), and Curis (CRIS) his top biotech picks for 2017, while Ulz chosesBioMarin Pharmaceutical (BMRN) andParatek Pharmaceuticals (PRTK).

  • [By Johanna Bennett]

    Will healthinsurers pay for Sarepta Therapeutics (SRPT) Exondys 51?

    Thats a question that several analysts have weighed on today. It appears that payors are still actively evaluating and reevaluating coverage of the Duchenne muscular dystrophy drug Exondys 51.

    Approved by the FDA in September, the drug has met with widespread pushback from insurers like Anthem (ANTM), Humana (HUM) and UnitedHealth Group (UNH) amid concerns about its efficacy. So while Sareptas share price has more than doubled over the past 12 months, it has made a sharp retreat, falling 50% to just under $32 a share since hitting a record high $63.73 a share in late September.

    But Cowen analyst Ritu Baral says the tide maybe turning, arguing that coverage denials wont be permanent.

    As SRPT management and our Neuromuscular Disease panelist indicated to us at our recent Healthcare Conference, payor discussions are continuing regarding Exondys 51 with manageable, increasingly positive feedback. Of the major plans we have seen coverage policies released for, only Anthem (including Blue Cross Blue Shield) had previously denied coverage of Exondys, though patients could petition for coverage via a standard appeal process (see further below). Based on their February Specialty Pharmacy Medical Management Prior Authorization Drug List, it appears Anthem will add Exondys 51 to its prior auth list as of 5/1. We think this is encouraging and indicative of the evolving payor landscape surrounding Exondys 51 and more broadly, DMD. Anthem’s pick-up, together with those such as United, which started coverage on 2/1, support the idea of accelerating new patient starts, suggested by SRPT last week at our Healthcare Conference.

    …But Coverage Denials Persist (For Now), Especially Among Non-Ambulatory Patients. While we think the overwhelming majority of amenable patients will eventually be covered for Exondys 51, we do note several social media anecdote

  • [By Chris Lange]

    Sarepta Therapeutics, Inc. (NASDAQ: SRPT) saw its shares make a handy gain on Tuesday following its presentation at the JPMorgan Healthcare Conference. The companys Duchenne muscular dystrophy (DMD) drug, Exondys 51, generated better than expected sales clocking in at $5.4 million in the fourth quarter. Previously, this DMD treatment was approved by the FDA just as recently as September 2016.